The telehealth company Hims & Hers has formally initiated its partnership with Novo Nordisk, making FDA-approved GLP-1 medications such as Wegovy and Ozempic available through its digital platform. This strategic move, however, arrives at a complex juncture. Just one day prior to the announcement, the U.S. Food and Drug Administration cleared Eli Lilly’s oral GLP-1 drug, Foundayo, for use. Notably, Foundayo’s introductory monthly price is set at $149, matching the base cost of Hims & Hers’ new membership program.
Revised Pricing and Intensifying Market Rivalry
Under its freshly launched subscription model, Hims & Hers charges customers $39 for the first month, followed by a recurring monthly fee of $149. This cost is separate from the medication itself, which carries a minimum additional charge of $149 per month. Consequently, the total expense for consumers is significantly higher than many market observers had anticipated.
This pricing strategy unfolds as competition intensifies. Eli Lilly’s Foundayo, scheduled for availability starting April 6, offers a practical advantage over existing injectable treatments: it does not require restrictions on food or fluid intake. This feature increases the competitive pressure on Hims & Hers, which is in the early stages of integrating Wegovy into its service offerings.
Should investors sell immediately? Or is it worth buying Hims & Hers?
Analyst Perspectives and Macroeconomic Headwinds
Financial analysts have expressed a cautious outlook. Bank of America analyst Allen Lutz has assigned a “Neutral” rating to the stock. He projects that the company’s GLP-1-related revenue could decline by 31% by 2026, citing a market shift away from compounded custom formulations toward approved brand-name drugs and new oral therapies. TD Cowen maintains a “Hold” stance but has reduced its price target for the stock to $23.
Beyond direct competition, broader economic factors are creating headwinds. The expiration of expanded tax credits under the Affordable Care Act has led to a substantial increase in health insurance premiums across the United States. This rise reduces the disposable income available for out-of-pocket healthcare expenditures, potentially impacting demand for services like those offered by Hims & Hers.
Market Reaction and Strategic Response
Investors reacted negatively to the developments, with the company’s shares declining 3.5% on Wednesday to close at $19.14. In response to the challenging landscape, Hims & Hers is focusing on making its treatments accessible through Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs). The effectiveness of this approach in defending its subscriber base against the direct-to-consumer offerings of major pharmaceutical manufacturers will become clearer with the release of upcoming quarterly financial results.
Ad
Hims & Hers Stock: Buy or Sell?! New Hims & Hers Analysis from April 3 delivers the answer:
The latest Hims & Hers figures speak for themselves: Urgent action needed for Hims & Hers investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 3.
Hims & Hers: Buy or sell? Read more here...
